公开(公告)号：US20240342507A1

公开(公告)日：2024-10-17

申请号：US18133962

申请日：2023-04-12

申请人： Beth Israel Deaconess Medical Center, Inc.

发明人： Ammar Sarwar ,  Joseph Ring

IPC分类号： A61N5/10 ,  A61K51/12 ,  G16H10/60

CPC分类号： A61N5/1071 ,  A61K51/1251 ,  A61N5/1002 ,  A61N5/1007 ,  G16H10/60 ,  A61N2005/1021

摘要： A microsphere delivery apparatus providing real-time measuring of delivered radioactivity during medical procedures utilizing radioactive emitting microspheres wherein an administration housing includes a holder to receive a vial containing microspheres for delivery to a patient, a detector holder to receive a radiation detector and a delivery tube assembly for transporting fluid containing the microspheres.

公开(公告)号：US20240209456A1

公开(公告)日：2024-06-27

申请号：US18557277

申请日：2022-04-25

申请人： BETH ISRAEL DEACONESS MEDICAL CENTER ,  UNIVERSITY OF PORTSMOUTH

发明人： Daniel Geoffrey TENEN ,  Annalisa DI RUSCIO ,  Alexander K. EBRALIDZE ,  Colyn CRANE-ROBINSON ,  Simone UMMARINO

IPC分类号： C12Q1/6886 ,  C12Q1/6804 ,  C12Q1/6851 ,  C12Q1/6869

CPC分类号： C12Q1/6886 ,  C12Q1/6804 ,  C12Q1/6869 ,  C12Q1/6851 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158

摘要： The present disclosure relates to compositions and methods of treating cancer in a subject in need thereof, relating to a specific non-coding RNA (ncRNA)-S Phase Early RNAs (SPEARs) or inhibitors thereof.

公开(公告)号：US11987790B2

公开(公告)日：2024-05-21

申请号：US16757296

申请日：2018-10-17

申请人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY ,  BETH ISRAEL DEACONESS MEDICAL CENTER

发明人： Melina Claussnitzer ,  Liang He ,  Manolis Kellis ,  Xinchen Wang

IPC分类号： C12N15/10 ,  C12N15/67 ,  C12N15/86 ,  C40B40/02

CPC分类号： C12N15/1051 ,  C12N15/67 ,  C12N15/86 ,  C40B40/02 ,  C12N2310/20 ,  C12N15/1051 ,  C12Q2521/10 ,  C12Q2525/204 ,  C12Q2535/122

摘要： Embodiments disclosed herein provide a general, scalable, high-throughput, and high-resolution approach for experimental dissection of regulatory regions and driver nucleotides in the context of human biology and disease. Applicants present HiDRA, a novel high-resolution global screen for transcriptional regulatory activity in accessible chromatin regions, enabling high-efficiency, high-throughput, and high-resolution inference of regulatory activity.

公开(公告)号：US20240158514A1

公开(公告)日：2024-05-16

申请号：US18489525

申请日：2023-10-18

申请人： Novartis AG ,  Beth Israel Deaconess Medical Center, Inc.

发明人： Anthony ROSENZWEIG ,  Jason D. ROH ,  David J. GLASS

IPC分类号： C07K16/28 ,  A61P9/04

CPC分类号： C07K16/2863 ,  A61P9/04 ,  C07K2317/76

摘要： The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.

公开(公告)号：US20240158466A1

公开(公告)日：2024-05-16

申请号：US18272092

申请日：2022-01-13

申请人： Beth Israel Deaconess Medical Center, Inc.

发明人： Elliot Chaikof ,  Richard D. Cummings

IPC分类号： C07K14/705 ,  A61K47/54 ,  A61K47/60 ,  A61P7/02 ,  C07K1/107

CPC分类号： C07K14/70564 ,  A61K47/549 ,  A61K47/60 ,  A61P7/02 ,  C07K1/1077

摘要： This disclosure relates to PEGylated selectin inhibitors, compositions, and methods related thereto. In certain embodiments, the disclosure relates to glycopeptides that contain one or more modified amino acids conjugated to a saccharide or polysaccharide and a polyethylene glycol (PEG) moiety. In some embodiments, the disclosure relates to uses of the PEGylated glycopeptides as anti-inflammatory, anti-thrombotic, or anti-metastatic agents.

公开(公告)号：US11926824B2

公开(公告)日：2024-03-12

申请号：US16827343

申请日：2020-03-23

申请人： Board of Regents, The University of Texas System ,  Beth Israel Deaconess Medical Center, Inc.

发明人： Raghu Kalluri ,  Sónia Melo

IPC分类号： C12N15/113 ,  A61K39/00 ,  C07K14/47 ,  C07K16/40 ,  C12Q1/6886 ,  G01N33/574 ,  G16B20/00

CPC分类号： C12N15/113 ,  C07K14/4703 ,  C07K16/40 ,  C12Q1/6886 ,  G01N33/57488 ,  G16B20/00 ,  A61K2039/505 ,  C12N2310/14 ,  C12N2310/141 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N2333/4704 ,  Y02A90/10

摘要： Methods for diagnosis and treatment of cancers by use of exosomes comprising miRNAs and precursors thereof. For example, in some aspects, a cancer may be diagnosed or evaluated by determining the miRNA content of exosomes in a sample from a subject or by detecting miRNA processing in exosomes.

公开(公告)号：US11869151B2

公开(公告)日：2024-01-09

申请号：US17585187

申请日：2022-01-26

申请人： Beth Israel Deaconess Medical Center

发明人： Eric T. Wong ,  Edwin Lok

IPC分类号： G06T15/00 ,  G06T17/20 ,  G06T7/10

CPC分类号： G06T17/20 ,  G06T7/10 ,  G06T2207/10088 ,  G06T2207/30016 ,  G06T2207/30096 ,  G06T2210/41

摘要： Aspects of the technology described herein relate to systems and techniques for finite element analysis of alternating electric fields such as tumor treating fields. A system may be configured to receive medical data of the patient, generate segmented medical data by performing segmentation using the medical data of the patient, generate a model for a transducer array configuration and the generated segmented medical data, wherein the transducer array configuration is configured to produce alternating electric fields, and determine one or more metrics of the alternating electric fields for each of the one or more transducer array configurations. The system may further compare the metrics to reference values and/or metrics of another transducer array configuration and/or determine and/or recommend a transducer array configuration based on the metrics.

公开(公告)号：US11795213B2

公开(公告)日：2023-10-24

申请号：US15666030

申请日：2017-08-01

申请人： Beth Israel Deaconess Medical Center, Inc.

发明人： Detlef Schuppan ,  Yvonne Junker ,  Towia Aron Libermann ,  Simon T. Dillon

IPC分类号： C12N15/82 ,  C07K16/18 ,  C07K16/16 ,  A61K39/00

CPC分类号： C07K16/18 ,  C07K16/16 ,  A61K2039/505 ,  C07K2317/76 ,  C12N15/8218 ,  C12N15/8245

摘要： The invention features the treatment of gastrointestinal disorders associated with an innate immune response triggered by alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CM1, CM2, CMa, CMd, CM 16, CMb, CMX1/CMX3, CMX2, and/or alpha amylase inhibitor 0.53 (0.53). To this end, the invention features pharmaceutical compositions including neutralizing antibodies to CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53, food products containing reduced levels of CM3, 0.19, CM1, CM2, CMa, CMd, CM1 6, CMb, CMX1/CMX3, CMX2, and/or 0.53 protein, the use of oral TLR4 inhibitors to block the effect of said alpha-amylase inhibitors, assays for identifying CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 content in food products, and assays for diagnosing subjects with a disorder related to CM3, 0.19, CM1, CM2, CMa, CMd, CM 16, CMb, CMX1/CMX3, CMX2, and/or 0.53 triggered innate immune responses.

公开(公告)号：US20230331847A1

公开(公告)日：2023-10-19

申请号：US17934441

申请日：2022-09-22

申请人： Dana-Farber Cancer Institute, Inc. ,  Beth Israel Deaconess Medical Center ,  President and Fellows of Harvard College

发明人： Gordon J. Freeman ,  Vassiliki A. Boussiotis ,  Xia Bu ,  Vikram R. Juneja ,  Arlene H. Sharpe ,  Nikolaos Patsoukis ,  Jessica Weaver ,  Laura Strauss

IPC分类号： C07K16/28 ,  C07K16/44 ,  G01N33/50 ,  G01N33/574

CPC分类号： C07K16/2818 ,  C07K16/44 ,  G01N33/5011 ,  G01N33/57492 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/70596 ,  G01N2440/14 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2500/20 ,  G01N2800/52

摘要： The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.

公开(公告)号：US11773142B2

公开(公告)日：2023-10-03

申请号：US16772045

申请日：2018-12-11

申请人： Beth Israel Deaconess Medical Center, Inc.

发明人： Dan H. Barouch ,  Peter Abbink ,  Mark Justin Iampietro ,  Menzo J. E. Havenga

IPC分类号： C07K14/075 ,  A61K35/761 ,  A61K39/235 ,  A61K31/7088 ,  C07K14/54 ,  C12N15/861

CPC分类号： C07K14/075 ,  A61K31/7088 ,  A61K35/761 ,  A61K39/235 ,  C07K14/5425 ,  C12N15/861

摘要： Featured are recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are simian (rhesus) adenoviruses having a low seroprevalence and high immunogenicity (when expressing, e.g., an antigenic polypeptide) relative to other adenoviruses and vectors thereof. Also featured are methods for producing the adenoviruses and methods of treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).